July 21, 2021 -- Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine within the African Union.
By the end of 2021, Pfizer and BioNTech expect that Biovac's facility in Cape Town will be incorporated into the vaccine supply chain. Biovac will obtain drug substance from facilities in Europe, with the manufacturing of finished doses to be completed in 2022.
At full operational capacity, the annual production will exceed 100 million finished doses per year, according to the company. All doses will be distributed exclusively within the 55 member states that make up the African Union.